Elevance Health, Inc. $ELV Shares Sold by Marathon Asset Management Ltd

Marathon Asset Management Ltd trimmed its position in shares of Elevance Health, Inc. (NYSE:ELV) by 7.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 246,811 shares of the company’s stock after selling 20,584 shares during the period. Elevance Health makes up approximately 3.3% of Marathon Asset Management Ltd’s holdings, making the stock its 7th biggest holding. Marathon Asset Management Ltd’s holdings in Elevance Health were worth $86,519,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Sound View Wealth Advisors Group LLC boosted its position in Elevance Health by 3.0% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock worth $354,000 after purchasing an additional 29 shares during the period. Fulton Breakefield Broenniman LLC boosted its position in Elevance Health by 3.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock worth $289,000 after purchasing an additional 29 shares during the period. Perigon Wealth Management LLC boosted its position in Elevance Health by 2.2% during the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock worth $481,000 after purchasing an additional 29 shares during the period. Savvy Advisors Inc. boosted its position in Elevance Health by 3.2% during the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock worth $343,000 after purchasing an additional 30 shares during the period. Finally, Detalus Advisors LLC boosted its position in Elevance Health by 1.8% during the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after purchasing an additional 31 shares during the period. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Stock Performance

NYSE:ELV opened at $402.32 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The firm has a 50-day moving average of $327.28 and a two-hundred day moving average of $334.81. The stock has a market cap of $87.37 billion, a P/E ratio of 17.11, a PEG ratio of 2.24 and a beta of 0.66. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $412.96.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period in the prior year, the company posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts expect that Elevance Health, Inc. will post 26.8 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Wall Street Analysts Forecast Growth

ELV has been the subject of a number of research reports. Weiss Ratings raised shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. Jefferies Financial Group decreased their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Truist Financial decreased their price target on shares of Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research report on Monday, April 13th. JPMorgan Chase & Co. upped their price target on shares of Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 28th. Finally, Leerink Partners set a $364.00 price objective on shares of Elevance Health in a research report on Thursday, April 23rd. Thirteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $384.58.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.